CVRx (CVRX) Scheduled to Post Earnings on Thursday

CVRx (NASDAQ:CVRXGet Rating) is set to announce its earnings results after the market closes on Thursday, January 26th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter. CVRx has set its FY 2022 guidance at EPS and its Q4 2022 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

CVRx (NASDAQ:CVRXGet Rating) last issued its quarterly earnings data on Tuesday, November 1st. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.08. The company had revenue of $6.19 million for the quarter, compared to analysts’ expectations of $5.87 million. CVRx had a negative return on equity of 31.40% and a negative net margin of 218.79%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Price Performance

Shares of NASDAQ:CVRX traded up $0.19 during trading on Tuesday, hitting $14.56. The company had a trading volume of 92,305 shares, compared to its average volume of 271,540. The stock has a market cap of $299.70 million, a price-to-earnings ratio of -7.17 and a beta of 0.70. The company has a fifty day simple moving average of $14.89 and a two-hundred day simple moving average of $10.98. CVRx has a one year low of $4.60 and a one year high of $19.94.

Insider Activity at CVRx

In other CVRx news, insider Paul Verrastro sold 4,600 shares of the firm’s stock in a transaction dated Monday, November 28th. The shares were sold at an average price of $11.94, for a total value of $54,924.00. Following the completion of the sale, the insider now owns 4,400 shares of the company’s stock, valued at $52,536. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 25.00% of the stock is currently owned by insiders.

Institutional Trading of CVRx

Institutional investors and hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its holdings in shares of CVRx by 2.3% in the second quarter. Price T Rowe Associates Inc. MD now owns 618,649 shares of the company’s stock worth $3,718,000 after purchasing an additional 14,173 shares during the last quarter. Vanguard Group Inc. grew its stake in CVRx by 17.7% in the 1st quarter. Vanguard Group Inc. now owns 463,935 shares of the company’s stock worth $2,779,000 after acquiring an additional 69,718 shares in the last quarter. BlackRock Inc. increased its position in shares of CVRx by 1.1% during the first quarter. BlackRock Inc. now owns 399,645 shares of the company’s stock worth $2,394,000 after acquiring an additional 4,233 shares during the period. State Street Corp raised its stake in shares of CVRx by 4.2% during the first quarter. State Street Corp now owns 247,656 shares of the company’s stock valued at $1,483,000 after acquiring an additional 10,096 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of CVRx by 685.4% in the first quarter. Renaissance Technologies LLC now owns 188,500 shares of the company’s stock valued at $1,129,000 after purchasing an additional 164,499 shares during the period. 51.16% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Piper Sandler raised their price target on CVRx from $14.00 to $18.50 in a research report on Monday, January 9th.

About CVRx

(Get Rating)

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF.

Further Reading

Earnings History for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.